Background: In patients with chronic kidney disease (CKD), there is an overproduction and accumulation of advanced glycation end-products (AGEs). Since AGEs may have detrimental effects on muscular trophism and performance, we evaluated whether they may contribute to the onset of sarcopenia in CKD patients. Methods: We enrolled 117 patients. The AGEs were quantified by fluorescence intensity using a fluorescence spectrophotometer and soluble receptor for AGE (sRAGE) isoforms by ELISA. As for the sarcopenia definition, we used the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Results: The average age was 80 ± 11 years, 70% were males, and the mean eGFR was 25 + 11 mL/min/1.73 m2. Sarcopenia was diagnosed in 26 patients (with a prevalence of 22%). The sarcopenic patients had higher levels of circulating AGEs (3405 ± 951 vs. 2912 ± 722 A.U., p = 0.005). AGEs were higher in subjects with a lower midarm muscle circumference (MAMC) (3322 ± 919 vs. 2883 ± 700 A.U., respectively; p = 0.005) and were directly correlated with the gait test time (r = 0.180, p = 0.049). The total sRAGE and its different isoforms (esRAGE and cRAGE) did not differ in patients with or without sarcopenia. Conclusions: In older CKD patients, AGEs, but not sRAGE, are associated with the presence of sarcopenia. There-fore, AGEs may contribute to the complex pathophysiology leading to the development of sarcope-nia in CKD patients.

Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease / P. Molinari, L. Caldiroli, E. Dozio, R. Rigolini, P. Giubbilini, M.M. Corsi Romanelli, G. Castellano, S. Vettoretti. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:7(2022), pp. 1489.1-1489.11. [10.3390/biomedicines10071489]

Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease

P. Molinari
Co-primo
;
L. Caldiroli
Co-primo
;
E. Dozio
Secondo
;
M.M. Corsi Romanelli;G. Castellano;
2022

Abstract

Background: In patients with chronic kidney disease (CKD), there is an overproduction and accumulation of advanced glycation end-products (AGEs). Since AGEs may have detrimental effects on muscular trophism and performance, we evaluated whether they may contribute to the onset of sarcopenia in CKD patients. Methods: We enrolled 117 patients. The AGEs were quantified by fluorescence intensity using a fluorescence spectrophotometer and soluble receptor for AGE (sRAGE) isoforms by ELISA. As for the sarcopenia definition, we used the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Results: The average age was 80 ± 11 years, 70% were males, and the mean eGFR was 25 + 11 mL/min/1.73 m2. Sarcopenia was diagnosed in 26 patients (with a prevalence of 22%). The sarcopenic patients had higher levels of circulating AGEs (3405 ± 951 vs. 2912 ± 722 A.U., p = 0.005). AGEs were higher in subjects with a lower midarm muscle circumference (MAMC) (3322 ± 919 vs. 2883 ± 700 A.U., respectively; p = 0.005) and were directly correlated with the gait test time (r = 0.180, p = 0.049). The total sRAGE and its different isoforms (esRAGE and cRAGE) did not differ in patients with or without sarcopenia. Conclusions: In older CKD patients, AGEs, but not sRAGE, are associated with the presence of sarcopenia. There-fore, AGEs may contribute to the complex pathophysiology leading to the development of sarcope-nia in CKD patients.
advanced glycation end-products (AGEs); chronic kidney disease (CKD); cleaved RAGE (cRAGE); endogenous secretory RAGE (esRAGE); sarcopenia; soluble receptor for AGE (sRAGE)
Settore MED/05 - Patologia Clinica
Settore MED/14 - Nefrologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
90 biomedicines-10-01489.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 452.66 kB
Formato Adobe PDF
452.66 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/933249
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact